New CAR-T therapy targets Hard-to-Treat myeloma
NCT ID NCT07620275
First seen Jun 02, 2026 · Last updated Jun 17, 2026 · Updated 2 times
Summary
This early-phase study tests a new treatment called KSVCBD injection for people with multiple myeloma that has come back or not responded to prior therapies. The treatment uses specially engineered immune cells (CAR-T cells) to find and attack cancer cells. The main goals are to check safety and see if the therapy shrinks tumors. Only 9 participants will be enrolled in this first-in-human trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Biotherapeutic Department of Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University
NOT_YET_RECRUITINGBeijing, China
Contact
-
National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College
NOT_YET_RECRUITINGTianjin, China
Contact
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.